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Editor, I read the recent publication on the use of diphenylhy-
dantoin for treatment of insulinoma by Nabbout et al. with great
interest [1]. Nabbout et al. concluded as follows: ‘‘We believe that
DPH is a potent inhibitor of insulin secretion and, thus, is suitable
as a temporary therapeutic measure in the preoperative period of
patients with insulinoma, as well as an alternative to surgery for
those who are not surgical candidates [1].” There are some spo-
radic reports on the success of using diphenylhydantoin [2,3].
However, there is a need for more evidence to reach this state-
ment. Success in a few cases might not warrant the efﬁcacy of this
new therapeutic approach for insulinoma.
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